Orexigen Therapeutics, Inc. (OREX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.03-0.31 (-7.14%)
As of 3:21 PM EDT. Market open.
People also watch:
VVUSARNAKERXMNKDACHN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open4.33
Prev Close4.34
Bid4.14 x 2300
Ask4.17 x 300
Day's Range4.00 - 4.39
52wk Range3.18 - 34.40
1y Target EstN/A
Market Cap58.78M
P/E Ratio (ttm)-0.75
Beta1.82
Volume134,313
Avg Vol (3m)281,001
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube9 days ago

    ETF’s with exposure to Orexigen Therapeutics, Inc. : August 15, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Orexigen Therapeutics, Inc. Here are 5 ETF’s with the largest exposure to OREX-US. Comparing the performance and risk of Orexigen Therapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
    Capital Cube12 days ago

    Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Orexigen Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Orexigen Therapeutics, Inc. – Arena Pharmaceuticals, Inc., VIVUS, Inc., Zafgen, Inc., Boston Scientific Corporation, Johnson & Johnson, Bristol-Myers Squibb Company and Athersys, Inc. (ARNA-US, VVUS-US, ZFGN-US, ... Read more (Read more...)

  • Associated Press20 days ago

    Orexigen reports 2Q loss

    On a per-share basis, the La Jolla, California-based company said it had a loss of $1.73. The drug developer for obesity and weight loss posted revenue of $7.8 million in the period. In the final minutes ...